• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
CMMB

CMMB

Chemomab Therapeutics Ltd.

NASDAQHealthcareBiotechnologyIL

USD1.72

-0.02 (-1.15%)

Rating:C+

Company Profile

CEO

Adi Mor George

IPO Date

2019-02-12

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

IL

Market Metrics

Open

$1.80

Prev. Close

$1.74

Day Low

$1.68

Day High

$1.80

52W Low

$1.35

52W High

$5.48

Market Cap

$0.01B

Volume

0.02M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

9

Avg Positive

47.3%

Avg Negative

1.4%

Avg Neutral

51.4%

News Feed

Chemomab Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update

PRNewsWire·8/13/2021·↑ positive

Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III

PRNewsWire·6/23/2021·↑ positive

CMMB Stock Price: Over 4% Increase Pre-Market Details

Pulse2·6/14/2021·↑ positive

Chemomab Therapeutics Is Heating Up And Could See A Move Soon

Benzinga·6/11/2021·↑ positive

Chemomab Announces Poster Presentation at the International Liver Congress 2021 (EASL)

PRNewsWire·6/10/2021·↑ positive

Chemomab Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update

PRNewsWire·5/13/2021·↑ positive

Chemomab to Present at Oppenheimer's Virtual Rare and Orphan Disease Summit

PRNewsWire·5/12/2021·↑ positive

Chemomab Announces Enrollment of First Patient in Phase 2a Study of CM-101 in Non-Alcoholic Steatohepatitis (NASH)

PRNewsWire·4/26/2021·↑ positive

Chemomab Therapeutics Stock Price Increased 111.13%: Why It Happened

Pulse2·4/8/2021·↑ positive